Table 2.
Association between the cumulative average TyG-BMI and CVD incidence
| Cumulative Average TyG-BMI | Quartiles | Continuous | ||||
|---|---|---|---|---|---|---|
| Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | P for trend | Per 1 SD increase | |
| Median | 164.6 | 190.3 | 213.5 | 249.1 | – | – |
| Cases, n (%) | 94 (6.9%) | 128 (9.5%) | 154 (11.4%) | 167 (12.3%) | – | – |
| Crude, OR (95% CI) | Reference | 1.401 (1.062–1.852) | 1.722 (1.319–2.258) | 1.886 (1.450–2.465) | < 0.001 | 1.255 (1.151–1.368) |
| Model 1, OR (95% CI) | Reference | 1.504 (1.137–1.995) | 1.900 (1.448–2.506) | 2.133 (1.625–2.816) | < 0.001 | 1.310 (1.197–1.432) |
| Model 2, OR (95% CI) | Reference | 1.505 (1.131–2.011) | 1.880 (1.406–2.524) | 2.066 (1.501–2.856) | < 0.001 | 1.309 (1.173–1.460) |
| Model 3, OR (95% CI) | Reference | 1.428 (1.070–1.913) | 1.635 (1.215–2.208) | 1.560 (1.118–2.185) | 0.018 | 1.168 (1.040–1.310) |
Model 1, adjusted for age and gender; Model 2, adjusted for age, gender, smoking status, drinking status, SBP, DBP, HbA1c, TC, HDL-c, LDL-c; Model 3, adjusted for variables included in Model 2 and residence (hukou), education level, marital status, hypertension, dyslipidemia, diabetes, liver disease, kidney disease, antihypertensive treatment, lipid-lowering treatment and hypoglycaemic treatment
TyG-BMI, triglyceride glucose-body mass index; OR, odds ratio; CI, confidence interval; SD, standard deviation